Article in Development (Cambridge, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 3 institutions in 2 countries.
Alix GoupilInstitut Curie, Paris Science et Lettres Research University, Centre National de la Recherche Scientifique, Unité Mixte de Recherche UMR144, Biology of Centrosomes and Genetic Instability Laboratory, 75005 Paris, France.
Jan Peter HeinenInstitute for Research in Biomedicine (IRB Barcelona), Cell Division Laboratory, Cancer Science Programme, The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain.ORCID 0000-0002-2867-4539
Riham SalameInstitut Curie, Paris Science et Lettres Research University, Centre National de la Recherche Scientifique, Unité Mixte de Recherche UMR144, Biology of Centrosomes and Genetic Instability Laboratory, 75005 Paris, France.
Fabrizio RossiInstitute for Research in Biomedicine (IRB Barcelona), Cell Division Laboratory, Cancer Science Programme, The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain.ORCID 0000-0003-1929-0688
Jose ReinaInstitute for Research in Biomedicine (IRB Barcelona), Cell Division Laboratory, Cancer Science Programme, The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain.
Carole PennetierInstitut Curie, Paris Science et Lettres Research University, Centre National de la Recherche Scientifique, Unité Mixte de Recherche UMR144, Biology of Centrosomes and Genetic Instability Laboratory, 75005 Paris, France.
Anthony SimonInstitut Curie, Paris Science et Lettres Research University, Centre National de la Recherche Scientifique, Unité Mixte de Recherche UMR144, Biology of Centrosomes and Genetic Instability Laboratory, 75005 Paris, France.
Patricia SkorskiInstitut Curie, PSL Research University, CNRS UMR 3215, INSERM U934, Stem Cells and Tissue Homeostasis Group, 75005 Paris, France.
Anxela LouzaoInstitute for Research in Biomedicine (IRB Barcelona), Cell Division Laboratory, Cancer Science Programme, The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain.ORCID 0000-0001-8888-0644
Allison J BardinInstitut Curie, PSL Research University, CNRS UMR 3215, INSERM U934, Stem Cells and Tissue Homeostasis Group, 75005 Paris, France.ORCID 0000-0002-0200-4465
Renata BastoInstitut Curie, Paris Science et Lettres Research University, Centre National de la Recherche Scientifique, Unité Mixte de Recherche UMR144, Biology of Centrosomes and Genetic Instability Laboratory, 75005 Paris, France.ORCID 0000-0001-5556-2770
Cayetano GonzalezInstitute for Research in Biomedicine (IRB Barcelona), Cell Division Laboratory, Cancer Science Programme, The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain.ORCID 0000-0002-5259-3608
Centre National de la Recherche Scientifique · FRInstitute for Research in Biomedicine · ESInstitució Catalana de Recerca i Estudis Avançats · ES
Funding
European Research Council 2011 294603Marie Curie
6 · The paper itself
Abstract
While testing for genome instability in Drosophila as reported by unscheduled upregulation of UAS-GFP in cells that co-express GAL80 and GAL4, we noticed that, as expected, background levels were low in most developing tissues. However, GFP-positive clones were frequent in the larval brain. Most of these clones originated from central brain neural stem cells. Using imaging-based approaches and genome sequencing, we show that these unscheduled clones do not result from chromosome loss or mutations in GAL80. We have named this phenomenon 'Illuminati'. Illuminati is strongly enhanced in brat tumors and is also sensitive to environmental conditions such as food content and temperature. Illuminati is suppressed by Su(var)2-10, but it is not significantly affected by several modifiers of position effect variegation or Gal4::UAS variegation. We conclude that Illuminati identifies a previously unknown type of functional instability that may have important implications in development and disease.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Illuminati: a form of gene expression plasticity in Drosophila neural stem cells. · full record | OpenQuestion